Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Panel Backs Novo’s Semaglutide after Recommendation Hold
A key health ministry advisory panel supported approval for Novo Nordisk’s once-weekly GLP-1 agent semaglutide on January 26 after it put a hold on recommending the drug last month, saying further deliberations are necessary for its label warnings for patients…
To read the full story
Related Article
- Novo to Develop New Dosages for Ozempic, 14-Day Prescription Limit Weighs
November 16, 2018
- Novo’s Ozempic Skips Listing for 3rd Time 8 Months after Approval
November 14, 2018
- Novo’s Ozempic Listing Plan Hobbled by 14-Day Prescription Rule?
August 24, 2018
- Novo Skips August Listing of Ozempic after Pricing Talks Fail
August 23, 2018
- Novo’s Semaglutide Up for MHLW Panel Review Jan. 26 after Approval Hold
January 15, 2018
- Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
December 5, 2017
REGULATORY
- LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
- Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
- Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
- LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
- LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…